Skip to main content
MediPharm Labs Corp. logo

MediPharm Labs Corp. — Investor Relations & Filings

Ticker · LABS LEI · 875500SIGS9KXW34K754 TSX Manufacturing
Open in API
Filings indexed 275 across all filing types
Latest filing 2020-09-02 Regulatory Filings
Country CA Canada
Listing TSX LABS

About MediPharm Labs Corp.

https://medipharmlabs.com/

MediPharm Labs Corp. is a full-service pharmaceutical company specializing in the development, formulation, processing, packaging, and distribution of precision-based, advanced cannabinoid products. Operating from Good Manufacturing Practices (GMP) certified facilities, the company focuses on producing pharma-quality cannabis Active Pharmaceutical Ingredients (API), concentrates, and derivative products. Utilizing strict manufacturing standards and ISO standard cleanrooms, MediPharm Labs ensures its offerings are pure, trusted, and precisely dosable for patients and consumers. Services include wholesale and white label platforms for domestic and international clients. The company holds a Pharmaceutical Drug Establishment License, enabling the manufacture of pharmaceutical drugs containing cannabis.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the completion of a research and innovation collaboration between MediPharm Labs and Georgian College. It describes the project details, goals, and outcomes related to data and analytics insights in cannabis extraction processes. There is no financial data, regulatory filing, or report attached or referenced as being published. The content is informational about a research collaboration and does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. It is not a report publication announcement since it does not mention any report being attached or published. The document is best classified as a general regulatory announcement or miscellaneous filing that does not fit other specific categories, which corresponds to Regulatory Filings (RNS).
2020-09-02 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing MediPharm Labs entering the Denmark medical cannabis market and securing new white-label supply customers. It discusses business agreements, market entry, and regulatory approvals but does not contain financial statements, detailed financial performance data, or management analysis. It is not a report, audit, earnings release, or regulatory filing. The content is primarily a business update and market entry announcement. Therefore, it fits best under the category of a general regulatory announcement or business update, which corresponds to Regulatory Filings (RNS) as a fallback category for miscellaneous filings that do not fit other specific categories.
2020-09-01 English
News release - English.pdf
Regulatory Filings Classification · 90% confidence The document is a press release announcing a new product launch and a strategic agreement between MediPharm Labs and Avicanna. It contains no financial statements, regulatory filings, voting results, or management changes. It is a corporate announcement about product development and partnership, not a financial report or regulatory filing. It does not fit into categories like Annual Report, Earnings Release, or Regulatory Filings. The content is promotional and informational about business activities and product offerings. Therefore, the best fitting category is Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2020-08-26 English
News release - English.pdf
Interim / Quarterly Report Classification · 100% confidence The document is a detailed announcement of MediPharm Labs' financial results for the second quarter of 2020, including comprehensive financial data such as revenue, gross profit, net loss, and adjusted EBITDA. It covers operational highlights, strategic progress, and outlook for the company. The presence of actual financial statements and substantive financial data for a quarter indicates this is a quarterly financial report. The document is lengthy (15,000 characters) and contains detailed financial and operational information, not merely an announcement or summary. Therefore, it fits the definition of an Interim / Quarterly Report (IR).
2020-08-19 English
News release - English.pdf
Interim / Quarterly Report Classification · 95% confidence The document is a detailed announcement of MediPharm Labs' financial results for the second quarter of 2020, including comprehensive financial data such as revenue, gross profit, net loss before tax, and adjusted EBITDA. It covers operational highlights, strategic progress, and outlook for the company. The presence of actual financial statements and substantive financial data for a quarterly period indicates this is a financial report for a period shorter than a full fiscal year. The document also mentions the availability of consolidated financial statements and management's discussion and analysis for the three and six months ended June 30, 2020, which aligns with an Interim / Quarterly Report. It is not merely an earnings release or a brief summary but a comprehensive report with detailed financial and operational information. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2020-08-13 English
Interim MD&A - English.PDF
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Management’s Discussion and Analysis for the Six and Three Months Ended June 30, 2020' and contains detailed financial commentary, operational highlights, and forward-looking statements for the quarterly period ending June 30, 2020. It references unaudited condensed interim consolidated financial statements and discusses financial results, non-IFRS measures, and operational performance. The document is approximately 15,000 characters long, indicating it is a substantive report rather than a brief announcement. The content aligns with the characteristics of an Interim / Quarterly Report (IR), which includes comprehensive financial data and management analysis for a period shorter than a full fiscal year. Therefore, the appropriate classification is 'IR'.
2020-08-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.